Ramosetron

ApprovedSmall molecule

Ramosetron is a small molecule that works as a Serotonin 3 (5-HT3) Receptor Antagonist.[2] It is being used across 12 indications, with its most advanced program in Approved.[1]

Ramosetron is one of 241 small molecule programs targeting Post Operative Nausea and Vomiting. It is currently in Approved.

Indications

Total Trials

Active Trials

240

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post Operative Nausea and VomitingActive, not recruiting

Bone FractureActive, not recruiting

Fecal IncontinenceActive, not recruiting

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

Nausea and VomitingUnknown

Coronary Artery BypassActive, not recruiting

Gastric CancerActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

HypotensionActive, not recruiting

Post Operative Nausea and VomitingPhase 3

Active, not recruiting

Bone FractureApproved

Active, not recruiting

Fecal IncontinencePhase 2

Active, not recruiting

Chemotherapy-Induced Nausea and VomitingPreclinical

Active, not recruiting

Total Knee ArthroplastyApproved

Active, not recruiting

Nausea and VomitingPreclinical

Unknown

Coronary Artery BypassPreclinical

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Irritable Bowel SyndromeApproved

Active, not recruiting

HypotensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Ramosetron

Astellas

Approved

37 2

Tuoyi

SSun Yat-sen University

Phase 3

18 3

Camptosar

EEastern Cooperative Oncology Group

Phase 3

5 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

N/ARecruiting

Low Anterior Resection Syndrome

NCT05577845

Clinical

Trials by Indication[1]

Nausea and vomiting15 trials

Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism

Completed·YYonsei University·Phase 4·NCT02480088·300 enrolled

Effect of Ramosetron in Prevention of Intrathecal Morphine Induced Nausea and Vomiting

Completed·TThammasat University·Phase 3·NCT02830906·99 enrolled

Efficacy of Dexamethasone Added to Ramosetron for Preventing Postoperative Nausea and Vomiting in Highly Susceptible Patients Following Spine Surgery

Completed·YYonsei University·Phase 4·NCT01013012·94 enrolled

Show 12 more trials

Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery

Completed·YYonsei University·Phase 4·NCT02478645·177 enrolled

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

Completed·KKyungpook National University Hospital·N/A·NCT02597907·88 enrolled

Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy

Unknown status·NNational Health Insurance Service Ilsan Hospital·Phase 3·NCT02011659·128 enrolled

Effect of Ramosetron on Post-discharge Nausea and Vomiting

Unknown status·SSeoul National University Bundang Hospital·N/A·NCT03409835·100 enrolled

Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting

Completed·SSeoul National University Hospital·Phase 3·NCT00971399·172 enrolled

Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery

Completed·YYonsei University·N/A·NCT01169805·105 enrolled

Ramosetron OD Tablet and Postdischarge Nausea and Vomiting

Unknown status·SSeoul National University Hospital·Phase 4·NCT04297293·138 enrolled

Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting

Completed·SSeoul National University Hospital·Phase 2·NCT01806948·96 enrolled

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery

Unknown status·HHallym University Medical Center·N/A·NCT02617121·120 enrolled

Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery

Completed·YYonsei University·N/A·NCT01825733·196 enrolled

Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

Completed·IIncheon St.Mary's Hospital·N/A·NCT01476280·100 enrolled

Irritable Bowel Syndrome2 trials

A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Completed· Astellas logo

Astellas·Phase 4·NCT00918411·98 enrolled

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Completed· Astellas logo

Astellas·Phase 4·NCT01225237·296 enrolled

Vomiting2 trials

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Completed· Astellas logo

Astellas·Phase 3·NCT00272285·287 enrolled

Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting

Completed·—·N/A·NCT02076529·51 enrolled

Hypotension1 trial

Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension

Unknown status·SSeoul National University Hospital·N/A·NCT01669213·100 enrolled

Bone Fracture1 trial

Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations

Terminated·SSeoul National University Hospital·Phase 4·NCT01637545·49 enrolled

16 more indications

Total Knee Arthroplasty1 trial

Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty

Completed·SSeoul National University Hospital·Phase 4·NCT01102491·153 enrolled

Prostatectomy1 trial

Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position

Completed·YYonsei University·N/A·NCT03232125·54 enrolled

Colorectal1 trial

Effect of Ramosetron on Bowel Motility After Colorectal Resection

Unknown status·KKyunghee University Medical Center·Phase 4·NCT01427127·64 enrolled

Coronary Artery Bypass1 trial

The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery

Completed·SSeoul National University Hospital·N/A·NCT02139241·114 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation

Unknown status·TThe Catholic University of Korea·Phase 2·NCT01788605·65 enrolled

Surgery1 trial

Effect of Ramosetron on Bowel Motility After Gynecological Surgery

Unknown status·KKyunghee University Medical Center·Phase 4·NCT02849483·88 enrolled

Low Anterior Resection Syndrome1 trial

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

Recruiting·SSeoul National University Hospital·N/A·NCT05577845·212 enrolled

Treatment1 trial

Ramosetron Pre-treatment for PONV and QT Prolongation

Completed·KKonkuk University Medical Center·Phase 4·NCT03278522·64 enrolled

Analgesia1 trial

Analgesia Effects of Nalbuphine vs Sulfentanil

Unknown status·FFudan University·N/A·NCT02604797·80 enrolled

Clinical Trial1 trial

Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome

Unknown status·SSeoul National University Hospital·Phase 1·NCT02869984·100 enrolled

Laparoscopic Surgery1 trial

Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery

Completed·YYonsei University·N/A·NCT03017222·80 enrolled

Patient-Controlled Analgesia1 trial

Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia

Completed·KKyungpook National University Hospital·N/A·NCT02416115·90 enrolled

Fecal Incontinence1 trial

The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

Unknown status·SSeoul National University Hospital·Phase 2/3·NCT06166615·148 enrolled

Dexamethasone1 trial

Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

Unknown status·HHallym University Medical Center·Phase 3·NCT01536691·338 enrolled

Female1 trial

Special Drug Use Surveillance of Irribow in Female Patients

Completed· Astellas logo

Astellas··NCT02612649·793 enrolled

Laparoscopic Cholecystectomy1 trial

The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy

Unknown status·SSeoul National University Bundang Hospital·N/A·NCT01041183·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Ramosetron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ramosetron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ramosetron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin 3 (5-HT3) Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

Ramosetron

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Nausea and vomiting15 trials

Irritable Bowel Syndrome2 trials

Vomiting2 trials

Hypotension1 trial

Bone Fracture1 trial

Total Knee Arthroplasty1 trial

Prostatectomy1 trial

Colorectal1 trial

Coronary Artery Bypass1 trial

Hematopoietic Stem Cell Transplantation1 trial

Surgery1 trial

Low Anterior Resection Syndrome1 trial

Treatment1 trial

Analgesia1 trial

Clinical Trial1 trial

Laparoscopic Surgery1 trial

Patient-Controlled Analgesia1 trial

Fecal Incontinence1 trial

Dexamethasone1 trial

Female1 trial

Laparoscopic Cholecystectomy1 trial

References

Drug Info

Quick Facts

Related News